Lipocine
LPCN
53 hedge funds and large institutions have $95.2M invested in Lipocine in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
147% more call options, than puts
Call options by funds: $672K | Put options by funds: $272K
13% more funds holding
Funds holding: 47 → 53 (+6)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
20% less capital invested
Capital invested by funds: $119M → $95.2M (-$23.6M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$1.52M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$674K |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
+$623K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$549K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$1.86M |
| 2 |
Renaissance Technologies
New York
|
-$1.61M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$923K |
| 4 |
VAM
Visium Asset Management
New York
|
-$733K |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
-$389K |
LPCN Hedge Fund Activity: Q1 2016 in Review
53 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2016, worth a combined $95.2M — down 20% from $119M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LPCN positions and 4 closed out — a net gain of 6 holders — while 17 added to existing stakes and 17 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $1.52M. The largest seller was Kingdon Capital Management, cutting an estimated $1.86M.
- 53 institutional investors held Lipocine (LPCN) as of Q1 2016, up from 47 in Q4 2015.
- Funds reported $95.2M of Lipocine stock for Q1 2016, down 20% quarter-over-quarter.
- 10 funds opened new Lipocine positions in Q1 2016 and 4 closed out, a net change of +6 holders.
- The largest Lipocine buyer in Q1 2016 was Gilder Gagnon Howe & Co, an estimated $1.52M added.
- The largest Lipocine seller in Q1 2016 was Kingdon Capital Management, an estimated $1.86M sold.
Based on aggregated 13F filings for Q1 2016.